Ovarian Cancer Clinical Trials in Houston

Showing 81-100 of 181 trials

A Study of ZN-c3 in Patients With Ovarian Cancer

NCT04516447

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc140 participantsStarted Oct 2020

Aurora, Colorado, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +21 more locations

TERMINATEDEARLY Phase 1< 1 mile

FPA150 in Patients With Advanced Solid Tumors

NCT03514121

This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.

Breast CancerOvarian CancerEndometrial Cancer+1 more

Five Prime Therapeutics, Inc.95 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +15 more locations

A Study of ZN-c3 in Patients With Ovarian Cancer

FPA150 in Patients With Advanced Solid Tumors

Ovarian Cancer Trials in Other Cities

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

SGI-110 in Combination With Carboplatin in Ovarian Cancer

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Other Conditions in Houston